EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma

Tian-Zhu Lu iD, Fu-Juan Zeng, Yu-Jun Hu, Min Fang, Fang-Yan Zhong iD, Bi-Juan Chen, Hao Zhang, Qiao-Juan Guo, Jian-Ji Pan, Xiao-Chang Gong, Shao Hui Huang, Zhao-Hui Liao und 2 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Tian-Zhu Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer H…. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Liver Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangxi Province Key R&D Program (Key Program), National Natural Science Foundation of China, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose To identify anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma (M1‐NPC). Materials and Methods All M1‐NPC treated with chemotherapy and/or radiotherapy between 2010 and 2019 from two centers (training and validation cohort) were included. The prognostic value of metastatic disease extent and involved organs for overall survival (OS) were assessed by several multivariable analyses (MVA) models. A new M1 classification was proposed and validated in a separate cohort who received immuno‐chemotherapy.

Results

A total of 197 M1‐NPC in the training and 307 in the validation cohorts were included for M1 subdivision study with median follow‐up of 46 and 57 months. MVA model with “≤2 organs/≤5 lesions” as the definition of oligometastasis had the highest C‐index (0.623) versus others (0.606–0.621). Patients with oligometastasis had better OS versus polymetastasis (hazard ratio [HR] 0.47/0.63) while liver metastases carried worse OS (HR 1.57/1.45) in MVA in the training/validation cohorts, respectively. We proposed to divide M1‐NPC into M1a (oligometastasis without liver metastases) and M1b (liver metastases or polymetastasis) with 3‐year OS of 66.5%/31.7% and 64.9%/35.0% in the training/validation cohorts, respectively. M1a subset had a better median progress‐free survival (not reach vs. 17 months, p < 0.001) in the immuno‐chemotherapy cohort ( n = 163).

Conclusion

Oligometastasis (≤2 organs/≤5 lesions) and liver metastasis are prognostic for M1‐NPC. Subdivision of M1‐NPC into M1a (oligometastasis without liver metastasis) and M1b (liver metastasis or polymetastasis) depicts the prognosis well in M1‐NPC patients who received immuno‐chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal NeoplasmsLiver NeoplasmsHumansNasopharyngeal CarcinomaPrognosisNeoplasm StagingRetrospective Studies

Stichwörter der Autor:innen

M1 categoriesimmunotherapynasopharyngeal carcinomaoligometastatic diseaseradiotherapy

Autor:innen und Institutionen

  • NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, N…
  • Department of Radiation Oncology, Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.
  • Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Tian-Zhu Lu, Fang-Yan Zhong

Förderung

  • Jiangxi Province Key R&D Program (Key Program)
  • National Natural Science Foundation of China
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • Open Fund for Scientific Research of Jiangxi Cancer Hospital

Zitieren

APA

Lu, T. Z., Zeng, F. J., Hu, Y. J., Fang, M., Zhong, F. Y., Chen, B. J., Zhang, H., Guo, Q. J., Pan, J. J., Gong, X. C., Huang, S. H., Liao, Z. H., Xia, Y., & Li, J. G. (2023). Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.6816

Vancouver

Lu TZ, Zeng FJ, Hu YJ, Fang M, Zhong FY, Chen BJ, et al. Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma. Cancer Medicine. 2023. doi:10.1002/cam4.6816

BibTeX
@article{Lu2023,
  author = {Lu, Tian-Zhu and Zeng, Fu-Juan and Hu, Yu-Jun and Fang, Min and Zhong, Fang-Yan and Chen, Bi-Juan and Zhang, Hao and Guo, Qiao-Juan and Pan, Jian-Ji and Gong, Xiao-Chang and Huang, Shao Hui and Liao, Zhao-Hui and Xia, Yunfei and Li, Jin-Gao},
  title = {Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6816}
}
Kostenlos starten →